Biocad: Melanoma trials
The registry lists 12 Melanoma studies with Biocad as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 5Phase 2 2Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06640530Phase 3
- A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06112808Phase 1
- Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
- Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05783882Phase 3
- A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaActive, not recruitingNCT05751928Phase 3
- Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced MalignanciesActive, not recruitingNCT05739006Phase 1
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaActive, not recruitingNCT05732805Phase 3
- Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03913923Phase 2
- Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic MelanomaCompletedNCT03472027Phase 1
- A Study of BCD-135 in Patients With Advanced Solid TumorsStatus unknownNCT03464032Phase 1
- International Trial of the Efficacy and Safety of BCD-100 in Patients With MelanomaStatus unknownNCT03269565Phase 2
- A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid TumorsStatus unknownNCT03050047Phase 1